Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at ifosfamide and doxorubicin for advanced soft tissue sarcoma (EORTC 62971)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was comparing doxorubicin with 2 different ways of having ifosfamide for advanced soft tissue sarcoma.
In this trial, the researchers compared doxorubicin with a drug called ifosfamide. They looked at 2 different ways of having ifosfamide.
The aims of the trial were to
- See which treatment worked best for advanced soft tissue sarcoma
- Learn more about the side effects
Summary of results
The trial team found that ifosfamide was no better at treating soft tissue sarcoma than doxorubicin.
The trial recruited 326 people
- A third had doxorubicin every 3 weeks
- A third had ifosfamide injections on 3 days every 3 weeks
- A third had ifosfamide as a continuous infusion over 3 days every 3 weeks
Side effects such as a drop in the number of blood cells, infections and changes to the
The trial team followed the progress of the people who took part for an average of over 3 and a half years. They found that the number of people whose cancer had responded to the treatment, and the number of people whose cancer had not come back, was about the same in all 3 groups.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Paul Lorigan
European Organisation for Research and Treatment of Cancer (EORTC)